QLF-32101

N/A

Report date: 2026/03/19 17:18:12

Base Information

Drug NameQLF-32101

Drug Alias NameQLF32101QLF-32101

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3Anti-C-Type lectin domain family 12 member A

TargetsT cell surface glycoprotein CD3C-Type lectin domain family 12 member A

Therapy Area/IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesQilu Pharmaceutical Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesQilu Pharmaceutical Co Ltd

Inactive CompaniesN/A

Active IndicationsMyelodysplastic SyndromesHematologic NeoplasmsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A